Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Management
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • Scientific Advisory Committee
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
      • Sponsor/ Advisor
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Category: Press releases

Onxeo will publish its full-year results on April 14, 2023

03/14/202303/14/2023

The annual general meeting will be held on June 6, 2023 Paris (France), March 14, 2023 – 6:00 pm CET […]

Onxeo: report on the Extraordinary General Meeting of February 6, 2023

02/06/202302/06/2023

Paris (France), February 6, 2023 – 7:30 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]

Onxeo advances its second lead candidate OX425 for the treatment of solid tumors

11/30/202211/30/2022

OX425 is a novel DDR Decoy Agonist which also mediates multiple immunostimulatory effects, making it a promising candidate for combination […]

Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities

09/13/202209/13/2022

Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally Cash position of €26.9 million as of June […]

High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study conducted by the European ITCC consortium and sponsored by Institut Curie

09/01/202209/01/2022

Paris (France), September 1st, 2022 – 8 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North[1]: ONXEO), a […]

Onxeo announces that Nasdaq approved the delisting of its shares from the First North Growth market in Copenhagen

08/30/202208/31/2022

Last day of trading on the First North Growth market on November 8, 2022 Listing on Euronext Growth Paris remains […]

Combined General Meeting of August 17, 2022: Onxeo shareholders approve withdrawal from the Nasdaq First North market in Copenhagen

08/17/202208/17/2022

Company to submit delisting request to Nasdaq   Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. […]

Combined General Meeting of August 17, 2022: availability of preparatory documents and participation & voting procedures

07/29/2022

Paris (France), July 29, 2022 – 06:30 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a […]

Onxeo announces a Combined General Meeting on August 17, 2022

07/12/202207/12/2022

Paris (France), July 12, 2022 – 07:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA

06/30/2022

Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors   Paris (France), […]

Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022

06/16/202206/16/2022

All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]

Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer

04/07/202204/06/2022

Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]

Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million

04/06/2022

Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]

Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022

03/31/202203/31/2022

AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]

Onxeo appoints Julien Miara as new interim CEO

01/03/202203/10/2022

Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]

Onxeo Announces its Financial Agenda for 2022

01/13/202203/10/2022

Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]

Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors

03/09/202203/10/2022

These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022   Paris (France), March 9, 2022 – 7:00 […]

New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments

12/08/202112/08/2021

These pioneering data were highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions   Paris (France), December 8, 2021 […]

Onxeo Continues to Strengthen its Board of Directors

11/23/202111/23/2021

Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member   Paris […]

Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector

10/14/202110/14/2021

Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy […]

Onxeo Reports its 2021 Half-Yearly Financial Results and Provides an Update on its Activities

07/29/202107/29/2021

Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]

Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board

07/29/202107/29/2021

Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee   […]

Onxeo: Report on the Combined General Meeting of June 10, 2021

06/10/2021

All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States

06/09/2021

This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]

Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts

05/31/202105/28/2021

This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]

Onxeo’s Combined General Meeting on June 10, 2021 in camera: availability of preparatory documents and live webcast login information

05/21/202105/21/2021

Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

Onxeo announces the success of its Rights Issue with €9.7 million raised

04/12/202105/21/2021

This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]

Onxeo Launches a Rights Issue to accelerate its R&D programs

03/10/202105/21/2021

This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]

Publication of the 2020 Annual Financial Report

04/23/2021

Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update

04/21/2021

Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]

Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020

02/27/202004/21/2021

Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo to Present New Preclinical Data at AACR 2021

04/08/202104/08/2021

Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]

Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children

02/04/202102/04/2021

This study is supported by a grant from the European Fight Kids Cancer program[1]   Paris (France), February 4, 2021 […]

Onxeo publishes Letter to Shareholders and provides update on its developments

02/02/202102/02/2021

Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]

Onxeo Obtains Non-Dilutive Financing of 5 Million Euros in the Form of State Guaranteed Loans

01/28/202102/01/2021

This financing extends the Company’s cash horizon to the 3rd quarter of 2022   Paris (France), January 28, 2021 – […]

2020 – Full-year report on the liquidity contract

01/08/202101/14/2021

2020 Full-year report on the liquidity contract

Onxeo to Attend Key Investor and Scientific Conferences

01/11/202101/10/2021

Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Announces its Financial Agenda for 2021

01/07/202101/08/2021

Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020

12/10/202012/10/2020

Paris (France), December 10, 2020 – 6 pm CET – Onxeo S.A. (ISIN: FR0010095596), (“Onxeo” or “the Company”), a clinical-stage […]

Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results

11/09/202011/09/2020

The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]

Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors

10/22/202010/22/2020

This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]

Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

10/21/202010/21/2020

Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]

Publication of the 2019 Half-Yearly Financial Report

07/31/201909/29/2020

Paris (France), July 31, 2019 – 7.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

Publication of the 2020 Half-Yearly Financial Report

09/29/202009/29/2020

Paris (France), September 29, 2020 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

Onxeo reports its financial results for the first half of 2020 and provides an update on its activities

09/17/2020

The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]

Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020

09/08/202009/08/2020

Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States

09/03/202009/03/2020

This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]

Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer

08/27/202008/27/2020

DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]

Transfer of the listing of Onxeo securities from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility

07/29/202007/30/2020

Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Announces Approval of the REVocan Study By Regulatory Authorities

05/29/202007/09/2020

The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]

Posts navigation

Older posts

NEWS & EVENTS

  • Press Releases
  • Events & Presentations
  • Shareholder Letters
  • Media
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

185 Alewife Brook Parkway
Suite 210, Cambridge, MA 02138
(617) 648-8674

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2023 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress